Ignite Creation Date:
2024-05-06 @ 8:34 AM
Last Modification Date:
2024-10-26 @ 12:02 PM
Study NCT ID:
NCT02768259
Status:
UNKNOWN
Last Update Posted:
2016-07-12
First Post:
2016-05-08
Brief Title:
Prevalence of Pulmonary Arterial Hypertension in Patients With Connective Tissue Diseases in Egyptian Patients
Sponsor:
Cairo University
Organization:
Cairo University
Study Overview
Official Title:
Prevalence of Pulmonary Arterial Hypertension in Patients With Connective Tissue in Egyptian Patients Single Center Study
Status:
UNKNOWN
Status Verified Date:
2016-07
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Measuring the incidence and prevalence of PAH in Egyptian patients with different types of MCD
Determination of survival the risk factors of mortality
Determination of survival the risk factors of mortality
Detailed Description:
PH is defined as a mean pulmonary artery pressure greater than 25 mmHg PAH can be assessed by different means however right heart catheterization RHC is the gold standard diagnostic method
Among the different subgroups of pulmonary arterial hypertension PAH those associated with connective tissue diseases CTDs are a specific entity with distinct hemodynamic and prognostic features reflecting the importance of a rheumatological assessment in PAH especially with the unfavorable prognostic impact in these patients
Compared to patients with idiopathic PAH patients with CTD-associated PAH have a higher mortality and a lower walking distance on the 6-minute walk test higher levels of B-type natriuretic peptide worse right ventricular function more left-sided heart dysfunction lower lung function and more pericardial disease
Thats why PAH screening is routinely performed in systemic sclerosis SSc and in other CTDs and also as suggested by international guidelines it is important to rule out CTDs in patients with PAH because patients diagnosed as idiopathic PAH iPAH may have an associated CTD previously unrecognized
Although the similarities in pathogenesis of PAH in CTD such as systemic sclerosis SSc systemic lupus erythematosus SLE and mixed connective tissue disease MCTD there are variabilities in outcomes in patients with CTD-associated PAH
Among the different subgroups of pulmonary arterial hypertension PAH those associated with connective tissue diseases CTDs are a specific entity with distinct hemodynamic and prognostic features reflecting the importance of a rheumatological assessment in PAH especially with the unfavorable prognostic impact in these patients
Compared to patients with idiopathic PAH patients with CTD-associated PAH have a higher mortality and a lower walking distance on the 6-minute walk test higher levels of B-type natriuretic peptide worse right ventricular function more left-sided heart dysfunction lower lung function and more pericardial disease
Thats why PAH screening is routinely performed in systemic sclerosis SSc and in other CTDs and also as suggested by international guidelines it is important to rule out CTDs in patients with PAH because patients diagnosed as idiopathic PAH iPAH may have an associated CTD previously unrecognized
Although the similarities in pathogenesis of PAH in CTD such as systemic sclerosis SSc systemic lupus erythematosus SLE and mixed connective tissue disease MCTD there are variabilities in outcomes in patients with CTD-associated PAH
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None